|[September 25, 2013]
Trevi Therapeutics Presents Data at the 7th World Congress on Itch
NEW HAVEN, Conn. --(Business Wire)--
Therapeutics, Inc. ("Trevi"), a clinical stage biotechnology company
focused on developing Nalbuphine
ER for chronic pruritus, presented data on nalbuphine at the 7th
World Congress on Itch.
Nalbuphine is a mixed mu antagonist/kappa agonist opioid. The effect of
nalbuphine on substance P induced scratching was studied by Trevi in the
mouse model. This model is relevant to antihistamine-resistant pruritus,
which is observed in patients with various dermatopathologies. Following
substance P administration in the untreted mice, itching began within
3-5 minutes from the pruritogen administration with the highest itch
intensity in the first 30 minutes post substance P injection. Following
nalbuphine administration, a significant reduction in itch (p<0.001) was
noted with a 43% reduction in itch at the 10 mg/kg dose and a 51%
reduction at the 30 mg/kg dose.
The published literature on nalbuphine suggests a centrally mediated
effect. The substance P mouse model conducted by Trevi suggests
nalbuphine can be effective as well in the treatment of peripherally
mediated pruritic conditions. This evidence of a centrally and
peripherally mediated effect potentially makes Nalbuphine ER a good
therapy for various chronic pruritic conditions.
Thomas Sciascia, MD, Trevi's co-founder and Chief Medical Officer, said,
"We are currently completing a Phase 1 trial in renally impaired
patients to establish safety in this patient population, and are
preparing to initiate an efficacy study in uremic pruritus in the first
half of 2014. In parallel, we plan to initiate a Phase 2 study in a
serious dermatologic condition, prurigo nodularis, in the same time
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical stage biotechnology company
focused on developing Nalbuphine ER for chronic pruritus (itch).
Pruritus develops in various dermatologic, metabolic, hematologic and
neuropathic conditions. The Company is pursuing two conditions for
clinical development: uremic pruritus and prurigo nodularis. Uremic
pruritus is a persistent and debilitating itch in patients on dialysis
that has been associated with increased mortality. Prurigo nodularis is
a chronic dermatologic condition characterized by pruritic nodules on
the skin that are independent of underlying etiology, but instead result
as a clinical reaction pattern due to long-term trauma of the pruritic
Nalbuphine ER is an oral extended release opioid with a unique opioid
receptor dual agonist/antagonist mechanism of action, which has been
shown in both animal studies and human clinical trials as being
effective in pruritus. Because of Nalbuphine ER's dual mechanism of
action, the company believes it can have broad utility in treating
chronic pruritus. Founded in 2011, Trevi is headquartered in New Haven,
For additional information, visit www.trevitherapeutics.com.
[ Back To Technology News's Homepage ]